# Lingyun Dai

## List of Publications by Citations



| 19 | 593 | 13 | 23 |
|---|---|---|---|
| papers | citations | h-index | g-index |
| 23 | 839 | 13.9 | 3.73 |
| ext. papers | ext. citations | avg, IF | L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 19 | Thermal proximity coaggregation for system-wide profiling of protein complex dynamics in cells. *Science*, **2018**, 359, 1170-1177 | 33.3 | 90 |
| 18 | Identifying purine nucleoside phosphorylase as the target of quinine using cellular thermal shift assay. *Science Translational Medicine*, **2019**, 11, | 17.5 | 81 |
| 17 | Modulation of Protein-Interaction States through the Cell Cycle. *Cell*, **2018**, 173, 1481-1494.e13 | 56.2 | 80 |
| 16 | miR-223 suppresses differentiation of tumor-induced CD11b+ Gr1+ myeloid-derived suppressor cells from bone marrow cells. *International Journal of Cancer*, **2011**, 129, 2662-73 | 7.5 | 71 |
| 15 | Dual blockade of the lipid kinase PIP4Ks and mitotic pathways leads to cancer-selective lethality. *Nature Communications*, **2017**, 8, 2200 | 17.4 | 46 |
| 14 | Horizontal Cell Biology: Monitoring Global Changes of Protein Interaction States with the Proteome-Wide Cellular Thermal Shift Assay (CETSA). *Annual Review of Biochemistry*, **2019**, 88, 383-408 | 29.1 | 39 |
| 13 | Antigen presentation by dendritic cells in tumors is disrupted by altered metabolism that involves pyruvate kinase M2 and its interaction with SOCS3. *Cancer Research*, **2010**, 70, 89-98 | 10.1 | 39 |
| 12 | Cellular thermal shift assay for the identification of drug-target interactions in the Plasmodium falciparum proteome. *Nature Protocols*, **2020**, 15, 1881-1921 | 18.8 | 27 |
| 11 | Monitoring structural modulation of redox-sensitive proteins in cells with MS-CETSA. *Redox Biology*, **2019**, 24, 101168 | 11.3 | 23 |
| 10 | An efficient proteome-wide strategy for discovery and characterization of cellular nucleotide-protein interactions. *PLoS ONE*, **2018**, 13, e0208273 | 3.7 | 22 |
| 9 | METTL7B Is Required for Cancer Cell Proliferation and Tumorigenesis in Non-Small Cell Lung Cancer. *Frontiers in Pharmacology*, **2020**, 11, 178 | 5.6 | 18 |
| 8 | CETSA in integrated proteomics studies of cellular processes. *Current Opinion in Chemical Biology*, **2020**, 54, 54-62 | 9.7 | 16 |
| 7 | LRRC19, a novel member of the leucine-rich repeat protein family, activates NF-kappaB and induces expression of proinflammatory cytokines. *Biochemical and Biophysical Research Communications*, **2009**, 388, 543-8 | 3.4 | 15 |
| 6 | Target identification and validation of natural products with label-free methodology: A critical review from 2005 to 2020. *Pharmacology & Therapeutics*, **2020**, 216, 107690 | 13.9 | 12 |
| 5 | Sources of diversity in T cell epitope discovery. *Frontiers in Bioscience - Landmark*, **2011**, 16, 3014-35 | 2.8 | 10 |
| 4 | Mutational Pattern in Multiple Pulmonary Nodules Are Associated With Early Stage Lung Adenocarcinoma. *Frontiers in Oncology*, **2020**, 10, 571521 | 5.3 | 1 |
| 3 | Recent advances in proteome-wide label-free target deconvolution for bioactive small molecules. *Medicinal Research Reviews*, **2021**, 41, 2893-2926 | 14.4 | 1 |

| | | | |
|---|---|---|---|
| 2 | CETSA interaction proteomics define specific RNA-modification pathways as key components of fluorouracil-based cancer drug cytotoxicity. *Cell Chemical Biology*, **2021**, | 8.2 | 1 |
| 1 | A small molecule interacts with pMAC-derived hydroperoxide reductase and enhances the activity of aminoglycosides. *Journal of Antibiotics*, **2021**, 74, 324-329 | 3.7 | 0 |